Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Conditions

• Gastric Cancer

Interventions

• DRUG: DP303c treatment
• DRUG: DP303c treatment（second-line of HER2-positive）
• DRUG: DP303c treatment （third-line of HER2-positive）
• DRUG: DP303c treatment（≥second-line of HER2 low expressing）
• DRUG: DP303c + PD-1/PD-L1 treatment

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.